A Phase Ib Study of Pembrolizumab in Bladder Cancer

Article
Conference|ESMO Congress

Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.

Clinical Pearls

Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.

  • 33 patients with urothelial tract cancer were enrolled on this trial.
  • A subset of patients experienced a decrease in tumor volume. There were 3 complete responses.
  • Overall survival data seen in this study were at the top bound of historical data.

<<<

View more from the 2014 ESMO Congress

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
First-Line Disitamab Vedotin/Toripalimab Shows Benefit in HER2+ la/mUC

First-Line Disitamab Vedotin/Toripalimab Shows Benefit in HER2+ la/mUC

Jordyn Sava
May 12th 2025
Article

Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.

Read More

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Jordyn Sava;Yu Fujiwara, MD
August 1st 2024
Podcast

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Listen

IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma

IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma

Jordyn Sava
May 7th 2025
Article

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Read More

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Jordyn Sava;Aaron Lisberg, MD
December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen

LBL-007/Toripalimab Combination Demonstrates Antitumor Activity and Safety in Nasopharyngeal Carcinoma

LBL-007/Toripalimab Combination Demonstrates Antitumor Activity and Safety in Nasopharyngeal Carcinoma

Tony Berberabe, MPH
May 1st 2025
Article

LBL-007 plus toripalimab showed manageable safety and favorable response in advanced solid tumors, notably higher in IO-naive nasopharyngeal carcinoma. Higher LAG-3 was linked to better responses.

Read More

Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery

Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery

Russ Conroy
April 30th 2025
Article

Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.

Read More